

Neostigmine

Statut de médicament essentiel

Description générale

Neostigmine is a reversible anticholinesterase agent indicated as a treatment for myasthenia gravis; and for use in the reversal of non-depolarizing muscle relaxants administered during surgery.

INN

Neostigmine bromide

Codes ATC

[N07AA01](#)

Type de médicament

Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 1977 ([TRS 615](#)) pour [Anticholinesterase reversible](#)

Ajouté en 1977 ([TRS 615](#)) pour [Myasthenia gravis](#)

Ajouté en 2025 ([TRS 1064](#)) pour [Myasthenia gravis](#)

Wikipédia

[Neostigmine](#)

DrugBank

[Neostigmine](#)

Recommandations

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Anticholinesterase reversible Myasthenia gravis](#)

Section

Medicines for myasthenia gravis

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Myasthenia gravis](#)